BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.
To ensure the smooth commercial launch of investigational RNAi therapy Patisiran, Alnylam Pharmaceuticals (ALNY) has been actively involved in building its manufacturing, quality, and distribution infrastructure in the US and Europe.
Apart from Gilead Sciences’ (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio.
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
United Therapeutics (UTHR) has developed a targeted strategy for a successful launch of its investigational drug device combination, the RemoSynch implantable pump system.
Following analysts’ projections, Soliris revenues in 3Q16 and 4Q16 should rise 9.0% and 10.0%, respectively, YoY to reach $725.9 million and $760.6 million, respectively.
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
With the continued uptake of Orkambi along with the label expansion efforts, Vertex Pharmaceuticals’s (VRTX) top line in fiscal 2016 is expected to reach $1.7 billion–$1.8 billion.
Soliris is Alexion Pharmaceuticals’ anchor of success. The drug was approved for paroxysmal nocturnal hemoglobinuria, or PNH, as a first indication in 2007.
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.
Alexion is expanding the label for its key drug Soliris. Along with Soliris, Alexion’s has several other key molecules in the advanced development stage.
There are ~27,000 eligible patients for Vertex Pharmaceuticals’ Kalydeco and Orkambi. However, Vertex is only currently treating one-third of patients.
In November 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received approval from the European Commission to treat patients 12 years and older with two copies of the F508del mutation.
Regeneron’s net margin during 3Q15 was ~18.5%. Historically, the net margin has been very volatile. It fluctuated from 8% to 24% for the last ten quarters.
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.
Alkermes plans a multi-pronged strategy for Aristada’s successful launch, which will involve flexible usage, effective pricing, and additional research.
